>"The size of the U.S. wave has given regulators and scientists an opportunity to better assess vaccine efficacy in children aged 6 months to 4 years old, said Dr. Scott Gottlieb, who sits on the board of the vaccine maker Pfizer."
>"The size of the U.S. wave has given regulators and scientists an opportunity to better assess vaccine efficacy in children aged 6 months to 4 years old, said Dr. Scott Gottlieb, who sits on the board of the vaccine maker Pfizer."